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Costs in Life Years GainedSvetlana Ratushnyak, MSc,1,2 Martine Hoogendoorn, PhD,3 Pieter H.M. van Baal, PhD1Introduction: Studies reporting on the cost-effectiveness of cancer screening usually account for
quality of life losses and healthcare costs owing to cancer but do not account for future costs and
quality of life losses related to competing risks. This study aims to demonstrate the impact of medi-
cal costs and quality of life losses of other diseases in the life years gained on the cost-effectiveness of
U.S. cancer screening.
Methods: Cost-effectiveness studies of breast, cervical, and colorectal cancer screening in the U.S.
were identified using a systematic literature review. Incremental cost-effectiveness ratios of the eligi-
ble articles were updated by adding lifetime expenditures and health losses per quality-adjusted life
year gained because of competing risks. This was accomplished using data on medical spending
and quality of life by age and disease from the Medical Expenditure Panel Survey (2011−2015)
combined with cause-deleted life tables. The study was conducted in 2018.
Results: The impact of quality of life losses and healthcare expenditures of competing risks in life
years gained incurred owing to screening were the highest for breast cancer and the lowest for cervi-
cal cancer. The updates suggest that incremental cost-effectiveness ratios are underestimated by
$10,300−$13,700 per quality-adjusted life year gained if quality of life losses and healthcare expen-
ditures of competing risks are omitted in economic evaluations. Furthermore, cancer screening pro-
grams that were considered cost saving, were found not to be so following the inclusion of medical
expenditures of competing risks.
Conclusions: Practical difficulties in quantifying quality of life losses and healthcare expenditures
owing to competing risks in life years gained can be overcome. Their inclusion can have a substan-
tial impact on the cost-effectiveness of cancer screening programs.
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/10.1016/j.amepre.2019.07.027S creening for breast, cervical, and colorectal canceris recommended in many countries. Economicevaluations have suggested that cancer screening
programs are cost effective and sometimes even cost
saving.1−10 Economic evaluations are important tools
to support decision making in health care by identify-
ing the most efficient way of deploying healthcare
resources using the incremental cost−effectiveness
ratio (ICER) as the main outcome.11 The ICER repre-
sents incremental costs per unit of incremental health
effects, which allows interventions to be ranked by rela-
tive cost-effectiveness. Ideally, the ICER is expressed asthe cost per quality-adjusted life year (QALY) gained to
allow the comparison of interventions across different
disease areas.12 The economic evaluations of screening
programs for cancer require models to simulate theof Preventive Medicine. Published by Elsevier Inc.
ttp://creativecommons.org/licenses/by-nc-nd/4.0/).
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sis on the remaining life expectancy, quality of life, and
cancer-related healthcare expenditures of a population.
For interventions that extend life, such as cancer
screening programs, it is essential to estimate the cost-
effectiveness correctly with the appropriate assessment
of costs, as well as the health effects in life years
gained.13−18 If an individual is saved from death (e.g.,
colorectal death) because of screening and lives addi-
tional years, during these gained years, there is the com-
peting risk of acquiring diseases unrelated to the
intervention under evaluation (e.g., Alzheimer disease).
As a result, a person may incur decrements in the quality
of life and consume health care, which can be labeled as
the incurred medical costs of other aging-related dis-
eases.18 If one ignores these quality of life losses and
healthcare costs of diseases in the life years gained in
economic evaluations, it implicitly assumes that the life
years gained are lived in perfect health, which leads to an
underestimation of costs, and an overestimation of health
benefits, and, consequently, to an underestimation of the
ICER.19 Considering that the life years gained because of
cancer screening are gained in old age, when the quality
of life is generally low and healthcare use is high, this issue
is of particular importance when assessing the cost-effec-
tiveness of cancer screening.
The inclusion of future unrelated medical costs has
been a topic of debate in the area of economic evalua-
tion, and, in practice, these costs are often ignored.13−18
However, there has been a growing consensus to include
such costs, as it has been shown that their exclusion
could lead to decisions that result in losses in population
health. Several pharmacoeconomic guidelines, such as
the newest U.S. guidelines from the Second Panel on
Cost-Effectiveness in Health and Medicine, now recom-
mend the inclusion of this type of cost in cost-effective-
ness analyses.11 In practice, many economic evaluations
have also ignored the impact of diseases in life years
gained on quality of life.20 The aim of this study is to
update the cost-effectiveness estimates of U.S. cancer
screening programs by including future medical costs
and quality of life losses for competing diseases in the
life years gained.METHODS
The study consisted of several steps. First, previously published
cost-effectiveness studies of screening for breast, cervical, and colo-
rectal cancers were searched in the literature. Second, age-specific
estimates of the quality of life and medical expenditures were esti-
mated. Third, the impact of screening on the length of life was
approximated using cause-deleted life tables. Finally, these results
were used to update the ICERs of the eligible articles found in Step
1. All the analyses were performed in 2018.December 2019Literature Search
First, cost-effectiveness studies of screening for breast, cervical,
and colorectal cancers in the U.S. were systematically searched in
MEDLINE. The search was conducted in May 2018. The search
strategy and review process are presented in Appendix Text 1
(available online). After assessing the eligible studies, data on the
incremental costs, incremental QALYs, and the age of starting
screening were extracted from the studies. To avoid double count-
ing, studies already including medical costs and quality of life
losses owing to competing risks in life years gained were excluded.Study Sample
Age-specific per capita estimates of the quality of life and healthcare
costs owing to competing diseases (all diseases except breast/colo-
rectal/cervical cancer) were estimated using data from the Medical
Expenditure Panel Survey (MEPS) from 2011 to 2015. MEPS is a
nationally representative survey of the U.S. civilian noninstitution-
alized population containing information on healthcare utilization;
medical conditions; and various social, demographic, and economic
characteristics.21 The health status of the respondents in the survey
is assessed using the standardized questionnaire Short-Form 12 ver-
sion 2. For this study, the 6-dimension health state classification
(SF-6D) was used to estimate health-related quality of life, which
was derived from the Short-Form 12 version 2 with the algorithm
proposed by Brazier et al.22 The expenditures in 2011−2014 were
adjusted to 2015 U.S. dollars using the Personal Consumption
Expenditure Health index.23 To model healthcare expenditures not
related to cancers, all the respondents who reported that they had
been diagnosed with breast, cervical, or colorectal cancer or cur-
rently had cancer according to their medical conditions data file
were excluded from the analysis. The final sample consisted of
107,431 respondents to model the quality of life and 127,273
respondents to model the healthcare expenditures.
Statistical Analysis
To estimate the per capita age-specific quality of life losses and
healthcare expenditures for the competing diseases, two-part
regression models were fitted, because the distributions of both
outcomes were skewed.24,25 The first part of the model predicted
the probability of the outcome variable being 1 (for the quality of
life data) or 0 (for the healthcare expenditure data). The second
part modeled the values for those who were not at the bounds of
the outcome variable. To model the quality of life, a logistic
regression was used for the first part and standard ordinary least
squares for the second part. For the healthcare expenditures, a
logistic regression model was used for the first part and a general-
ized linear model with log link (gamma distribution) for the sec-
ond part. Models were fitted separately for male and female
respondents. To capture the nonlinear pattern of the quality of
life and expenditures by age, the models included the age and pol-
ynomials of age as predictors.
As there was no access to the original models of the eligible
articles, the impact of screening on length of life was approxi-
mated using cause-deleted life tables.26,27 Life tables enable the
estimation of survival curves and life expectancy based on the
population mortality rates. A cause-deleted life table provides esti-
mates of the life expectancy of the population if cancer deaths
were eliminated. For the unscreened cohorts, it was assumed that
the mortality rates were not affected by screening, so the all-cause
794 Ratushnyak et al / Am J Prev Med 2019;57(6):792−799mortality rates were used to calculate life expectancy. For the
screened cohorts, it was assumed that because of screening, cancer
was eliminated as a cause of death, and the life expectancy was
then recalculated as if the eliminated cancer had never occurred.
The recalculated life expectancy was then compared with the all-
cause life expectancy to approximate the life years gained because
of the screening. By linking age-specific per capita estimates of the
quality of life and healthcare costs to these life table cohorts,
quality-adjusted life expectancy (QALE) and medical costs of
competing risks in the life years gained were estimated. This
approximation works well because the main outcome of interest
was the ratio of healthcare expenditure of competing risk per
QALE and not the absolute amounts. Prediction intervals were
estimated using parametric bootstrapping with the regression
coefficients and their covariance as input.28
Deaths (all causes and cancer-specific) by single-year age group
and sex were derived from the Centers of Disease Control and Pre-
vention WONDER database for the last available year, 2016.29 The
Human Mortality Database was used to extract the population size
by single-year age group and sex because, for the subset of those
aged 85≥100 years, the population sizes and consequently the
mortality rates, were not available.30 The cause-deleted mortality
rates were calculated by subtracting cancer-specific mortality rates
from the all-cause mortality rates. Cohorts were followed up from
the age of starting screening until age 100 years or death. Life tables
were constructed separately for breast, cervical, and colorectal
cancer screening programs.
Published cost-effectiveness estimates from the original studies
were updated by adding lifetime healthcare expenditures and
quality of life losses owing to competing risks to the ICERs with
the formula: ICER ¼ D costD QALYsþ DCCsDQALE (Appendix Text 3
available online), where Dcosts are the incremental costs extracted
from the original articles and inflated to the year 2015 using the
Personal Consumption Expenditure Health index;23 ΔQALYs are
the incremental QALYs extracted from the original articles, and
DCC and ΔQALE are the estimated incremental future healthcare
expenditures and gains in the QALE of the competing risks esti-
mated using the life tables. Lifetime health effects and healthcare
costs were discounted with the 3% annual rate suggested by the
Second Panel on Cost-Effectiveness in Health and Medicine.11
Note that this updating procedure is similar to the one used in
several papers by Meltzer and colleagues.15,31,32
Several univariate sensitivity analyses were performed. In the
first, cancer mortality was decreased with 10% instead of eliminat-
ing the mortality for all cancers. In the other sensitivity analysis,
the impact of using different estimates of spending33 and quality
of life34 was assessed.Figure 1. (a) Actual (dots) and predicted mean QoL and (b)
HCEs in U.S. dollars by age for males and females.
HCE, healthcare expenditure; QoL, quality of life.RESULTS
The literature search identified 669 articles, of which 71
seemed eligible based on the title. Based on the full-text
articles, 17 studies were found to be eligible, of which
another 7 were excluded because the study did not compare
screening with no screening (n=5), QALYs and healthcare
costs were presented in total (n=1), or both the costs and
quality of life losses of competing risks were already included
(n=1).35 In total, 10 articles reporting on the cost-effectiveness of screening for breast, cervical, and colorectal
cancer in the U.S. were included in this study.36−45
The mean observed and predicted values for health-
related quality of life and healthcare expenditures by age
for men and women are presented in Figure 1. The qual-
ity of life decreased with age for both sexes, and the
healthcare expenditures increased with age presuming
higher costs for men than for women at advanced ages.
More details on the estimated coefficients of the two-part
models for the quality of life and healthcare expenditures
can be found in Appendix Text 2 available online.
The estimates of the gains in the life expectancy,
QALE, and lifetime healthcare expenditures of compet-
ing risks for various ages of starting screening are shown
in Table 1. The gains in life expectancy and in QALE
were the highest for breast cancer and the lowest for cer-
vical cancer. The healthcare expenditures of the compet-
ing risks incurred from screening were also the highest
for breast cancer and the lowest for cervical cancer. The
incremental costs per QALE gained reflect how much
the actual ICER in the original publication is underesti-
mated. Values for the costs per QALE for the base case
analysis ranged from $10,300 per QALE gained for a
cohort screened for cervical cancer at age 18 years towww.ajpmonline.org
Table 1. Estimated Incremental Results of Including Competing Risks (Base Case Analysis and Sensitivity Analyses), Starting
Age of Screening
Breast cancer
Cervical cancer Colorectal cancer
Variable Age 40 years Age 50 years Age 18 years Age 30 years Age 50 years
Base case analysis
ΔLE, undiscounted 0.397 0.347 0.0531 0.051 5 0.209
ΔQALE, undiscounted 0.283 (0.281,
0.285)
0.245 (0.244,
0.247)
0.0388 (0.0386,
0.0389)
0.037 5 (0.0374,
0.037 7)
0.150 (0.149,
0.151)
ΔHCE, undiscounteda 3,980 (3,730,
4,310)
3,591 (3,344,
3,893)
470 (450, 510) 460 (440, 500) 2,260 (1,950,
2,670)
Costs/QALY gained,
discounted (ΔHCE/ΔQALE)
12,710 13,620 10,260 10,510 13,700
10% decrease mortalityb
ΔLE, undiscounted 0.039 0.035 0.005 0.005 0.021
ΔQALE, undiscounted 0.028 0.0244 0.0039 0.0038 0.015
ΔHCE, undiscounteda 396 358 47 46 220
Costs/QALY gained,
discounted (ΔHCE/ΔQALE)
12,700 13,620 10,260 10,510 13,660
Different quality of life and cost valuesc
ΔQALE, undiscounted 0.302 0.2614 0.0417 0.0403 0.161
ΔHCE, undiscounteda 9,140 8,419 987 969 5,040
Costs/QALY gained,
discounted (ΔHCE/ΔQALE)
25,120 27,692 18,469 18,970 26,780
aIn 2015 U.S. dollars.
bInstead of eliminating cancer as a cause, cancer mortality is only reduced by 1%.
cCosts taken from Lassman et al.(2014)33 and quality of life values taken from Heijink et al.(2011)34.
HCE, healthcare expenditures; LE, life expectancy; QALE, quality adjusted life expectancy; QALY, quality adjusted life years.
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rectal cancer at age 50 years. Table 1 also shows that
results are quite robust to different assumptions with the
exception of using cost values from a different study,
which increased the costs per QALE by a factor of 2.
Table 2 shows the original and updated ICERs for the
studies identified in the literature review. Only a selection
of the results is presented, but all the results are available
in Appendix Table 4 (available online). All the screening
alternatives are displayed in relative cost-effectiveness
based on 2015 U.S. dollar ICERs from the most to the
least cost effective. The selected studies suggest that colo-
rectal cancer screening strategies were the most cost effec-
tive, followed by cervical cancer screening and breast
cancer screening strategies. The updated ICERs, including
the quality of life losses and healthcare expenditures of
competing risks, were higher compared with the original
ICERs. Furthermore, by including the healthcare expendi-
tures of competing risks in the life years gained, interven-
tions that appeared to be cost saving were no longer cost
saving, as the additional spending in the life years gained
outweighed the savings in the care for cancer.DISCUSSION
This study aimed to update the cost-effectiveness of
breast, cervical, and colorectal cancer screeningDecember 2019programs in the U.S. by including quality of life losses
and healthcare costs owing to disease other than cancer
in the life years gained. The review on published studies
reporting the cost-effectiveness of breast, cervical, and
colorectal cancer showed that almost all the studies did
not account for medical expenditures and quality of life
losses owing to competing diseases in life years gained
at old age. The ICERs of breast, cervical, and colorectal
cancer screening were underestimated by approximately
$10,300−$13,700 per QALY gained if the quality of life
losses and healthcare expenditures of competing risks
are omitted in economic evaluations. The ICERs of the
breast and colorectal cancer screening programs were
more sensitive to the exclusion of the healthcare expen-
ditures of competing risks, whereas the ICERs of cervical
cancer screening were more sensitive to the exclusion of
quality of life losses. This suggests that not including the
healthcare expenditures of competing risks would favor
the interventions that extend life over the interventions
that improve the quality of life. The impact is greater
when the interventions extend life expectancy more than
when they improve the quality of life. In the U.S., there
are no clearly defined thresholds to define whether an
intervention is cost effective or not,46 but thresholds of
$50,000 and $100,000 are common. For the interven-
tions with the ICERs close to the threshold used, these
updates could make a substantial impact on the cost-
Table 2. The Impact of Including Competing Risks on the Cost-Effectiveness of Cancer Screening Programs (Selection of Results)
Screening strategy (reference)
Screening started
and ended at age,
years
DCosts (in U.S. $
year), original study
ΔQALY, original
study
ICER, original
studya
Updated
ICERb
Updated
ICERc
Updated
ICERd
FS/FIT every 3 years36 From 50 to 80 139 (2010) 0.078 3 Cost saving Cost saving 9,555 11,779
Sigmoidoscopy/FOBT38 From 50 to 80 44 (2010) 0.079 1 602 788 11,961 14,302
mSEPT9-3well38 From 50 to 80 520 (2010) 0.061 9 9,088 11,900 23,605 22,788
Vaginal HPV DNA screening with
cytology triage, triennial40
From 18 to 85 Not available Not available 11,546 14,438 Not available 21,802
Stool DNA39 From 50 to 80 1,423 (2014) 0.090 3 15,935 20,864 25,885 29,634
Pap, triennial42 From 20 to 75 1,815 (2000) 0.153 4 17,349 21,795 18,003 27,606
Digital mammography, biennial44 From 40 to 74 1,720 (2012) 0.042 42,523 55,665 42,554 55,229
MM/2 &CBE/1, interval between
examinations 245
From 40 3,400 (assumed 2003) 0.069 65,582 85,850 84,243 78,288
aInflated to 2015 U.S. $ ($ per QALY gained).
bOnly quality of life losses included using the formula ICER ¼ D costD QALY  LEscreenedQALEscreened.cOnly costs of competing risks included using the formula
ICER ¼ D costD QALY þ Dhealthcare expenditures of competing risksDQALY.dQuality of life losses and HCE of competing risks included using the formula: ICER ¼ D costD QALY þ Dhealthcare expenditures of competing risksDQALE.
CBE, clinical breast examination; FOBT, fecal occult blood testing; FS/FIT, flexible sigmoidoscopy/fecal immunochemical testing; HPV, human papilloma virus; ICER, incremental cost−effectiveness
ratio; LE, life expectancy; MM, mammography; mSEPT9-3well, methylated Septin 9 DNA plasma assay; QALE, quality-adjusted life expectancy; QALY, quality-adjusted life year.
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Ratushnyak et al / Am J Prev Med 2019;57(6):792−799 797effectiveness of these interventions. Furthermore, some
interventions that were considered cost saving were no
longer cost saving after the inclusion of medical expendi-
tures of competing risks. It should be noted that also in
Europe, the standard seems to be to exclude both costs
and quality of life losses of competing risks in the life
years gained when evaluating cancer screening.
With regard to costs, the findings were consistent with
previous studies showing that not considering healthcare
expenditures for competing risks underestimated the life-
time healthcare costs.16−18 De Kok et al.19 showed that
the ICER of cancer screening increased by approximately
€4,000 per life year gained when the healthcare costs for
competing risks were taken into account. To compare
their results with the current findings, healthcare expendi-
tures for competing risks per life year gained are calcu-
lated based on Table 1, which ranged from $7,600 to
$10,000. The difference could be explained by methodo-
logic differences, such as different discount rates, and by
the fact that U.S. healthcare expenditures are generally
higher than those in the Netherlands. With regard to the
quality of life, the findings by age and sex were also con-
sistent with previous studies.47−49
Limitations
The study has some limitations. One is that the quality of
life and costs were regressed on age, whereas previous
studies suggest that the quality of life and healthcare costs
depend on age and time to death.50−53 These studies found
that modeling the costs and quality of life exclusively con-
ditional on age results in an overestimation of the incre-
mental healthcare costs and quality of life losses. With the
MEPS data set, it was not possible to estimate the impact
of the time to death on health spending and quality of life.
At the same time, the MEPS data do not fully represent
the costs and quality of life related to the end of life
because individuals in institutions (for example, in hospi-
ces) are excluded from the survey. In a sensitivity analysis,
cost estimates from Lassman and colleagues33 were used,
who also used other data sources in addition to the MEPS
to reflect the spending of the institutionalized population.
Consequently, the impact on the ICER is also about dou-
ble. The impact of competing risk might still be underesti-
mated in this study, because competing risks were
assumed to be equal to those of the general population.
However, cancer survivors might run higher risks on some
disease. Another limitation is that the quality of life and
healthcare expenditures were estimated by simultaneously
excluding respondents with breast, cervical, and colorectal
cancer. Therefore, the final estimates of the healthcare
expenditures and quality of life are unrelated to breast, cer-
vical, and colorectal cancer. However, it is expected that
the results would not change much, because the healthcareDecember 2019expenditure and quality of life losses for competing dis-
eases depend on the prevalence of these competing dis-
eases in the general population, which would not be
changed dramatically when all the cancers were excluded
simultaneously or separately for each cancer. The validity
of the updating framework crucially depends on the age
pattern at which mortality is impacted by screening. It was
assumed that the impact at which the screening affects
mortality follows the same pattern as the cause-specific
cancer mortality. If this assumption does not hold, it indi-
cates that the impact on the ICER is overestimated if mor-
tality is impacted at a lower age because of screening. If
the screening impacts mortality at a higher age than
assumed, the impact is underestimated.CONCLUSIONS
Despite the limitations, these findings have important
practical and policy implications. The values of the qual-
ity of life losses and healthcare expenditures of compet-
ing risks that were estimated could be used in economic
evaluations of interventions targeted at breast, cervical,
and colorectal cancer in the U.S. In addition, it was
shown how these estimates can be readily included in
economic evaluations of such programs. The ideal way
to include them in economic evaluations is to use appro-
priately developed tools to facilitate standardized
inclusion.54
This study demonstrated the importance of including
quality of life losses for competing diseases and the
healthcare expenditures of competing risks in economic
evaluations of life-extending interventions to support
better medical decision making. The updates increased
the ICERs in absolute terms and changed the relative
ordering of the alternatives. In jurisdictions where inter-
ventions are accepted based on their cost per QALY, the
inclusion of quality of life losses and healthcare expendi-
tures for competing diseases may affect the decision
about the acceptability of a given intervention. Decisions
based on underestimated ICERs could translate into
inefficient allocation of healthcare resources.ACKNOWLEDGMENTS
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